{"id":4318,"date":"2018-03-26T10:00:30","date_gmt":"2018-03-26T08:00:30","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/"},"modified":"2020-07-03T09:40:25","modified_gmt":"2020-07-03T07:40:25","slug":"gentherapie-fuer-erblich-bedingte-netzhautdegeneration","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/","title":{"rendered":"Gene therapy for hereditary retinal degeneration"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Gene therapy for hereditary retinal degeneration<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]SIRION Biotech and Acucela enter into a development agreement[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]March 2018[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”4314″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 SIRION Biotech GmbH[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]SIRION Biotech GmbH is engaged in the development of gene therapies with adeno-associated Viruses (AAV), for example for use in the treatment of eye diseases[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]The SIRION Biotech GmbH, a world leader in virus based technology innovation and gene delivery expert providing custom services to commercial partners worldwide, announced that it signed a two year development agreement with Acucela Inc., a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide, to establish optimized AAV vectors for clinical applications in ocular gene therapy. With this cooperative effort, Acucela bolsters its move into the fast growing gene therapy market to find a genetic cure for retinitis pigmentosa (RP), which is the most common form of inherited retinal degeneration. Key terms of the agreement include milestone payments to SIRION Biotech, with additional royalties to be paid on net sales from resulting products or therapies.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

The SIRION Biotech GmbH, a world leader in virus based technology innovation and gene<\/span> delivery expert providing custom services to commercial partners<\/span><\/span><\/p>\n","protected":false},"author":1,"featured_media":4312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[286],"tags":[],"class_list":["post-4318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-izb-news"],"yoast_head":"\nGene therapy for hereditary retinal degeneration - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gene therapy for hereditary retinal degeneration\" \/>\n<meta property=\"og:description\" content=\"The SIRION Biotech GmbH, a world leader in virus based technology innovation and gene delivery expert providing custom services to commercial partners worldwide, announced that it signed a two year development agreement with Acucela Inc., a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide, to establish optimized AAV vectors for clinical applications in ocular gene therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/\" \/>\n<meta property=\"og:site_name\" content=\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-26T08:00:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-07-03T07:40:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/00-Beitragsbild-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"255\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"p534396\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"p534396\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/\"},\"author\":{\"name\":\"p534396\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/person\\\/12499d818c4e3f59388b94103f0a527e\"},\"headline\":\"Gene therapy for hereditary retinal degeneration\",\"datePublished\":\"2018-03-26T08:00:30+00:00\",\"dateModified\":\"2020-07-03T07:40:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/\"},\"wordCount\":330,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/00-Beitragsbild-1.jpg\",\"articleSection\":[\"IZB News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/\",\"name\":\"Gene therapy for hereditary retinal degeneration - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/00-Beitragsbild-1.jpg\",\"datePublished\":\"2018-03-26T08:00:30+00:00\",\"dateModified\":\"2020-07-03T07:40:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/00-Beitragsbild-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/00-Beitragsbild-1.jpg\",\"width\":400,\"height\":255,\"caption\":\"human-eye\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IZB Biotech News\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/izb-biotech-news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IZB News\",\"item\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/izb-biotech-news\\\/izb-news\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Gene therapy for hereditary retinal degeneration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"name\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB\",\"description\":\"Innovations- und Gr\u00fcnderzentrum Biotechnologie\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#organization\",\"name\":\"F\u00f6rdergesellschaft IZB mbH\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.izb-online.de\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/izb-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"F\u00f6rdergesellschaft IZB mbH\"},\"image\":{\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.izb-online.de\\\/en\\\/#\\\/schema\\\/person\\\/12499d818c4e3f59388b94103f0a527e\",\"name\":\"p534396\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gene therapy for hereditary retinal degeneration - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/","og_locale":"en_US","og_type":"article","og_title":"Gene therapy for hereditary retinal degeneration","og_description":"The SIRION Biotech GmbH, a world leader in virus based technology innovation and gene delivery expert providing custom services to commercial partners worldwide, announced that it signed a two year development agreement with Acucela Inc., a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide, to establish optimized AAV vectors for clinical applications in ocular gene therapy.","og_url":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/","og_site_name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","article_published_time":"2018-03-26T08:00:30+00:00","article_modified_time":"2020-07-03T07:40:25+00:00","og_image":[{"width":400,"height":255,"url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/00-Beitragsbild-1.jpg","type":"image\/jpeg"}],"author":"p534396","twitter_card":"summary_large_image","twitter_misc":{"Written by":"p534396","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/#article","isPartOf":{"@id":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/"},"author":{"name":"p534396","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/person\/12499d818c4e3f59388b94103f0a527e"},"headline":"Gene therapy for hereditary retinal degeneration","datePublished":"2018-03-26T08:00:30+00:00","dateModified":"2020-07-03T07:40:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/"},"wordCount":330,"commentCount":0,"publisher":{"@id":"https:\/\/www.izb-online.de\/en\/#organization"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/#primaryimage"},"thumbnailUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/00-Beitragsbild-1.jpg","articleSection":["IZB News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/","url":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/","name":"Gene therapy for hereditary retinal degeneration - Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","isPartOf":{"@id":"https:\/\/www.izb-online.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/#primaryimage"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/#primaryimage"},"thumbnailUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/00-Beitragsbild-1.jpg","datePublished":"2018-03-26T08:00:30+00:00","dateModified":"2020-07-03T07:40:25+00:00","breadcrumb":{"@id":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/#primaryimage","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/00-Beitragsbild-1.jpg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/03\/00-Beitragsbild-1.jpg","width":400,"height":255,"caption":"human-eye"},{"@type":"BreadcrumbList","@id":"https:\/\/www.izb-online.de\/en\/gentherapie-fuer-erblich-bedingte-netzhautdegeneration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.izb-online.de\/en\/"},{"@type":"ListItem","position":2,"name":"IZB Biotech News","item":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/"},{"@type":"ListItem","position":3,"name":"IZB News","item":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/izb-news\/"},{"@type":"ListItem","position":4,"name":"Gene therapy for hereditary retinal degeneration"}]},{"@type":"WebSite","@id":"https:\/\/www.izb-online.de\/en\/#website","url":"https:\/\/www.izb-online.de\/en\/","name":"Innovations- und Gr\u00fcnderzentrum Biotechnologie IZB","description":"Innovations- und Gr\u00fcnderzentrum Biotechnologie","publisher":{"@id":"https:\/\/www.izb-online.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.izb-online.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.izb-online.de\/en\/#organization","name":"F\u00f6rdergesellschaft IZB mbH","url":"https:\/\/www.izb-online.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","contentUrl":"https:\/\/www.izb-online.de\/wp-content\/uploads\/2020\/06\/izb-logo.svg","width":1,"height":1,"caption":"F\u00f6rdergesellschaft IZB mbH"},"image":{"@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.izb-online.de\/en\/#\/schema\/person\/12499d818c4e3f59388b94103f0a527e","name":"p534396"}]}},"_links":{"self":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts\/4318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/comments?post=4318"}],"version-history":[{"count":12,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts\/4318\/revisions"}],"predecessor-version":[{"id":11645,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/posts\/4318\/revisions\/11645"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media\/4312"}],"wp:attachment":[{"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/media?parent=4318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/categories?post=4318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.izb-online.de\/en\/wp-json\/wp\/v2\/tags?post=4318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}